

Figure 1

[illegible]

Figure 2A

		10	20	30	40	50	
HUMAN	1	MLLSKFGSLA	HLCPGGVDH	LPVKILOPAK	ADKESFEKAY	QVGAVLGSGG	50
RAT	1	MLLSKFGSLA	HLCPGGVDH	LPVKILOPAK	ADKESFEKVY	QVGAVLGSGG	50
MOUSE	1	MLLSKFGSLA	HLCPGGVDH	LPVKILOPAK	ADKESFEKVY	QVGAVLGSGG	50
		60	70	80	90	100	
HUMAN	51	FGTVYAGSRI	ADGLPVAVKH	VVKERVTEWG	SLGGATVPLE	VVLLRKVGAA	100
RAT	51	FGTVYAGSRI	ADGLPVAVKH	VVKERVTEWG	SLGGMAVPLE	VVLLRKVGAA	100
MOUSE	51	FGTVYAGSRI	ADGLPVAVKH	VVKERVTEWG	SLGGVAVPLE	VVLLRKVGAA	100
		110	120	130	140	150	
HUMAN	101	GGARGVIRLL	DWFERPDGFL	LVLERPEPAQ	DLFDFTITERG	ALDEPLARRF	150
RAT	101	GGARGVIRLL	DWFERPDGFL	LVLERPEPAQ	DLFDFTITERG	ALDEPLARRF	150
MOUSE	101	GGARGVIRLL	DWFERPDGFL	LVLERPEPAQ	DLFDFTITERG	ALDEPLARRF	150
		160	170	180	190	200	
HUMAN	151	FAQVLA AVRH	CHSCGVVHRD	IKDENLLVDL	RSSELKLIDF	GSGALLKDTV	200
RAT	151	FAQVLA AVRH	CHNCGVVHRD	IKDENLLVDL	RSSELKLIDF	GSGAVLKDTV	200
MOUSE	151	FAQVLA AVRH	CHNCGVVHRD	IKDENLLVDL	RSSELKLIDF	GSGAVLKDTV	200
		210	220	230	240	250	
HUMAN	201	YTDFDGTRVY	SPPEWIRYHR	YHGRSATVWS	LGVLLYDMVC	GDIPFEODEE	250
RAT	201	YTDFDGTRVY	SPPEWIRYHR	YHGRSATVWS	LGVLLYDMVC	GDIPFEODEE	250
MOUSE	201	YTDFDGTRVY	SPPEWIRYHR	YHGRSATVWS	LGVLLYDMVC	GDIPFEODEE	250
		260	270	280	290	300	
HUMAN	251	ILRGRLFFRR	RVSPECQQLI	RWCLSLRPSE	RPSLDQIAAH	PWMLGADGGA	300
RAT	251	ILRGRLFFRR	RVSPECQQLI	EWCLSLRPSE	RPSLDQIAAH	PWMLGTEGSV	300
MOUSE	251	ILRGRLFFRR	RVSPECQQLI	EWCLSLRPSE	RPSLDQIAAH	PWMLGTEGSV	300
		310	320				
HUMAN	301	PESCDLRLCT	LDPDDVASTT	SSSESL			
RAT	301	PENCDLRLCA	LDTDDGASTT	SSSESL			
MOUSE	301	PENCDLRLCA	LDTDDGASTT	SSSESL			

Figure 3

		10	20	30	40	50	
Pim-1	1	MLLSKINSLA	HL-RAAPCND	LHATKLAPGK	-EKEPLESQY	QVGPILGSGG	50
Pim-2	1	MLTKFLQ—	—GPPAP	PGTPTPPGG	KDRRAFEAEY	RLGPILGKGG	50
Pim-3	1	MLLSKFGSLA	HLGPGGGVDH	LPVKILQPAK	ADKBSFEKAY	QVGAVLGSGG	50
		60	70	80	90	100	
Pim-1	51	FGSVYSGIRV	SDNLPVAIKH	VEKDRISDWG	ELPNGTRVPM	EVVLLKKVSS	100
Pim-2	51	FGTVFAGHRL	TDRLQVAIKV	IPRNRVLGWS	PLSDSVTCPL	EVALLWKVGA	100
Pim-3	51	FGTVYAGSRI	ADGLPVAVKH	VVKERVTEWG	SL-GGATVPL	EVVLLRKVGA	100
		110	120	130	140	150	
Pim-1	101	-GFSGVIRL	LDWFERPDSF	VLIERPEPV	QDLFDFTTER	GALQRELARS	150
Pim-2	101	GGGHGPGVIRL	LDWFETQEGF	MLVLERPLPA	QDLFDYITEK	GPLGEGPSRC	150
Pim-3	101	AGGARGVIRL	LDWFERPDGF	LLVLERPEPA	QDLFDFTTER	GALDEPLARR	150
		160	170	180	190	200	
Pim-1	151	FFWQVLEAVR	HCHNCGVLHR	DIKDENILID	LNRGELKLID	FGSGALLKDT	200
Pim-2	151	FFGQVVAAIQ	HCHSRGVVHR	DIKDENILID	LRRGCAKLID	FGSGALLHDE	200
Pim-3	151	FFAQVLA AVR	HCHSCGVVHR	DIKDENLLVD	LRSGELKLID	FGSGALLKDT	200
		210	220	230	240	250	
Pim-1	201	VYTDGTRV	YSPPEWIRYH	RYHGRSAAVW	SLGILLYDMV	CGDIPFERHDE	250
Pim-2	201	PYTDGTRV	YSPPEWISRH	QYHALPATVW	SLGILLYDMV	CGDIPFERDQ	250
Pim-3	201	VYTDGTRV	YSPPEWIRYH	RYHGRSATVW	SLGVILLYDMV	CGDIPFEQDE	250
		260	270	280	290	300	
Pim-1	251	RIIRGQVFFR	QRVSSECQHL	IRWCLALRPS	DRPTFERIQN	HPWMQDVLL-	300
Pim-2	251	EILBAELHFP	AHVSPDCCAL	IRCLAPKPS	SRPSLEKILL	DPWMQTPAED	300
Pim-3	251	EILRGRLIFR	RRVSECQQL	IRWCLSLRPS	ERPSLDQIAA	HPWMLGADGG	300
		310	320	330	340		
Pim-1	301	P—QET	ABEHL—	—HSLSPG	P—	SK	
Pim-2	301	VTPQLQRRP	CPGLVLATL	SLAWPGLAPN	GQKSHPMAMS	QG	
Pim-3	301	A—PES	CDLRL—	—CTLDPD	DVASTTSSE	SL	

Figure 4

BEST AVAILABLE COPY




Figure 5

BEST AVAILABLE COPY





Figure 6

A



B



Figure 7





Figure 8

TREATMENT WITH
LIPOFECTAMINE ALONE



RANDOM RNA
FRAGMENT



Pim-3 siRNA



Figure 9




Figure 10